Altimmune (ALT) Cash & Equivalents (2010 - 2026)
Altimmune (ALT) posted quarterly Cash & Equivalents of $97.6 million for Q1 2026, up 98.68% year-over-year from $49.1 million in Q1 2025, and up 122.92% quarter-over-quarter from $43.8 million in Q4 2025.
Altimmune (ALT) Cash & Equivalents (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Cash & Equivalents for 17 consecutive years, with $97.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 98.68% year-over-year to $97.6 million; the TTM figure through Mar 2026 stood at $97.6 million (up 98.68% YoY), while the FY2025 annual figure was $43.8 million, up 18.49% from the prior year.
- Cash & Equivalents rose to $97.6 million in Q1 2026 per ALT's latest filing, from $43.8 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $183.1 million in Q2 2025 and bottomed at $31.5 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $95.5 million across 5 years, with a median of $97.6 million in 2026.
- Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 72.65% — and 2025, when it surged 220.36%.
- Altimmune's Cash & Equivalents stood at $111.1 million in 2022, then advanced by 21.62% to $135.2 million in 2023, then slumped by 72.65% to $37.0 million in 2024, then grew by 18.49% to $43.8 million in 2025, then jumped by 122.92% to $97.6 million in 2026.
- Business Quant data shows ALT's Cash & Equivalents at $97.6 million in Q1 2026, $43.8 million in Q4 2025, and $61.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 63.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.05 Mn |
| Mar 31, 2026 | 97.64 Mn |
| Dec 31, 2025 | 43.80 Mn |
| Sep 30, 2025 | 61.24 Mn |
| Jun 30, 2025 | 183.15 Mn |
| Mar 31, 2025 | 49.15 Mn |
| Dec 31, 2024 | 36.97 Mn |
| Sep 30, 2024 | 31.52 Mn |
| Jun 30, 2024 | 57.17 Mn |
| Mar 31, 2024 | 79.02 Mn |
| Dec 31, 2023 | 135.16 Mn |
| Sep 30, 2023 | 86.90 Mn |
| Jun 30, 2023 | 102.39 Mn |
| Mar 31, 2023 | 104.72 Mn |
| Dec 31, 2022 | 111.13 Mn |
| Sep 30, 2022 | 127.50 Mn |
| Jun 30, 2022 | 135.89 Mn |
| Mar 31, 2022 | 179.98 Mn |
| Dec 31, 2021 | 190.34 Mn |
| Sep 30, 2021 | 174.90 Mn |